Ramanathan M, Weinstock-Guttman B, Nguyen L T, Badgett D, Miller C, Patrick K, Brownscheidle C, Jacobs L
Department of Pharmaceutics, 543 Cooke Hall, State University of New York at Buffalo, 14260-1200, Buffalo, NY, USA.
J Neuroimmunol. 2001 Jun 1;116(2):213-9. doi: 10.1016/s0165-5728(01)00308-3.
To use DNA arrays to identify differences in gene expression associated with relapsing-remitting (RR) MS.
Total RNA was isolated from monocyte depleted peripheral blood mononuclear cells of 15 RR MS patients and 15 age- and sex-matched controls. The RNA was reverse transcribed to radiolabeled cDNA and the resultant cDNA was used to probe a DNA array containing over 4000 named human genes. The binding of radiolabeled cDNA to the probes on the array was measured by phosphorimager.
Of more than 4000 genes tested, only 34 were significantly different in RR-MS patients from controls. Of these, 25 were significantly increased and 9 significantly decreased in the RR MS patients. Twelve of these genes have inflammatory and/or immunological functions that could be relevant to the MS disease process. The potentially relevant genes that were elevated (15% to 28%) were P protein, LCK, cAMP responsive element modulator, IL-7 receptor, matrix metalloproteinase-19, M130 antigen, and peptidyl-prolyl isomerase. Those that were significantly decreased (15% to 35%) were SAS transmembrane 4 superfamily protein, STRL22 (C-C chemokine receptor 6), AFX protein, DNA fragmentation factor-45 and immunoglobulin gamma 3 (Gm marker).
The RR-MS disease effect was relatively restricted and most of the mRNAs tested were not different from the normal controls. However, there were significant differences identified in the expression of a subset of mRNAs, including 13 with inflammatory/immune functions that could be relevant to MS. The systematic use of DNA arrays can provide insight into the dynamic cellular pathways involved in MS pathogenesis and its phenotypic heterogeneity.
使用DNA阵列来识别与复发缓解型(RR)多发性硬化症相关的基因表达差异。
从15例RR型多发性硬化症患者以及15例年龄和性别匹配的对照者的单核细胞耗竭外周血单核细胞中分离总RNA。将RNA逆转录为放射性标记的cDNA,并将所得的cDNA用于探测包含4000多个已命名人类基因的DNA阵列。通过荧光成像仪测量放射性标记的cDNA与阵列上探针的结合情况。
在检测的4000多个基因中,RR型多发性硬化症患者与对照者之间只有34个基因存在显著差异。其中,RR型多发性硬化症患者中有25个基因显著上调,9个基因显著下调。这些基因中有12个具有炎症和/或免疫功能,可能与多发性硬化症的疾病进程相关。上调的潜在相关基因(升高15%至28%)有P蛋白、LCK、cAMP反应元件调节剂、IL-7受体、基质金属蛋白酶-19、M130抗原和肽基脯氨酰异构酶。显著下调的基因(降低15%至35%)有SAS跨膜4超家族蛋白、STRL22(C-C趋化因子受体6)、AFX蛋白、DNA片段化因子-45和免疫球蛋白γ3(Gm标记)。
RR型多发性硬化症的疾病影响相对有限,大多数检测的mRNA与正常对照无差异。然而,在一部分mRNA的表达中发现了显著差异,包括13个具有炎症/免疫功能且可能与多发性硬化症相关的基因。DNA阵列的系统应用能够深入了解多发性硬化症发病机制及其表型异质性所涉及的动态细胞途径。